Deeper Knowledge, Faster

  • Uncover prior art in expired and abandoned patents
  • Obtain formulation and manufacturing information
  • Drug patents in 130+ countries
➤ Start Trial

or, See Plans & Pricing

Upgrade to enjoy subscriber-only features like email alerts and data export. See the Plans and Pricing

Serving leading biopharmaceutical companies globally:

Deloitte
Moodys
Daiichi Sankyo
Merck
Farmers Insurance
McKinsey
Chinese Patent Office
Colorcon
Cerilliant
Julphar

Generated: January 22, 2018

DrugPatentWatch Database Preview

HALFLYTELY Drug Profile

« Back to Dashboard

Which patents cover Halflytely, and when can generic versions of Halflytely launch?

Halflytely is a drug marketed by Braintree and is included in one NDA. There is one patent protecting this drug and two Paragraph IV challenges.

The generic ingredient in HALFLYTELY is bisacodyl; polyethylene glycol 3350; potassium chloride; sodium bicarbonate; sodium chloride. There are five drug master file entries for this compound. One supplier is listed for this compound. Additional details are available on the bisacodyl; polyethylene glycol 3350; potassium chloride; sodium bicarbonate; sodium chloride profile page.
Summary for HALFLYTELY
Drug patent expirations by year for HALFLYTELY

US Patents and Regulatory Information for HALFLYTELY

Applicant Tradename Generic Name Dosage NDA Approval Date TE Type RLD RS Patent No. Patent Expiration Product Substance Delist Req. Exclusivity Expiration
Braintree HALFLYTELY bisacodyl; polyethylene glycol 3350; potassium chloride; sodium bicarbonate; sodium chloride FOR SOLUTION, TABLET, DELAYED RELEASE;ORAL 021551-003 Jul 16, 2010 DISCN Yes No ➤ Subscribe ➤ Subscribe ➤ Subscribe
Applicant Tradename Generic Name Dosage NDA Approval Date TE Type RLD RS Patent No. Patent Expiration Product Substance Delist Req. Exclusivity Expiration

This preview shows a limited data set. Subscribe for full access, or try a Free Trial

Paragraph IV (Patent) Challenges for HALFLYTELY
Drugname Dosage Strength RLD Submissiondate
➤ Subscribe For Oral Solution and Delayed-release Tablet 210 g, 5.6 g, 0.74 g, 2.86 g and 5 mg (1 Tablet Regimen) ➤ Subscribe 7/30/2010
➤ Subscribe For Oral Solution and Delayed- 210 g, 5.6 g, 0.74 g, 2.86 g and 5 mg ➤ Subscribe 1/28/2008

For more information try a trial or see the plans and pricing

Serving leading biopharmaceutical companies globally:

Chubb
Cantor Fitzgerald
Express Scripts
Mallinckrodt
Dow
Healthtrust
US Army
McKesson
Medtronic

Drugs may be covered by multiple patents or regulatory protections. All trademarks and applicant names are the property of their respective owners or licensors. Although great care is taken in the proper and correct provision of this service, thinkBiotech LLC does not accept any responsibility for possible consequences of errors or omissions in the provided data. The data presented herein is for information purposes only. There is no warranty that the data contained herein is error free. thinkBiotech performs no independent verifification of facts as provided by public sources nor are attempts made to provide legal or investing advice. Any reliance on data provided herein is done solely at the discretion of the user. Users of this service are advised to seek professional advice and independent confirmation before considering acting on any of the provided information. thinkBiotech LLC reserves the right to amend, extend or withdraw any part or all of the offered service without notice.

botpot